FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, and concerns a method for cardiac function recovery following acute myocardial infarction with infarction involvement, wherein the method involves introducing into an individual a non-swelling, recovered population of autogenous mononuclear cells enriched with CD34+ cells containing a subpopulation, at least 0.5×106 of high-active CD34+ cells expressing XCR-4 possessing CXCR-4 mediated chemotactic activity and shifting in response to SDF-1; using the pharmaceutical composition for preparing a therapeutic agent for the cardiac function recovery in the individual after acute myocardial infarction with an infarction inflammation, wherein the pharmaceutical composition contains the above recovered population of the autogenous mononuclear cells.
EFFECT: group of inventions provides less infarction involvements due to preventing cardiomyocyte loss following acute myocardial infarction by improving perfusion and preventing apoptosis.
78 cl, 13 ex, 4 dwg, 36 tbl
